---

Thyroid Swelling - Treatment

---

1. Classification of Thyroid Swelling

---

2. Diffuse Non-Toxic (Simple) Goiter

• Iodine deficiency: Iodine replacement causes variable regression, depending on the duration and degree of fibrosis or autonomous function that may have developed.
• Levothyroxine (LT4): TSH suppression is rarely effective for reducing size and risks inducing subclinical/overt thyrotoxicosis.
• Surgery: Reserved for tracheal compression, obstruction of the thoracic inlet, or cosmetic reasons. Subtotal or near-total thyroidectomy followed by LT4 replacement. - Harrison's Principles, p. 3083

---

3. Nontoxic Multinodular Goiter (MNG)

• Conservative management is appropriate for most asymptomatic euthyroid patients.
• T4 suppression is rarely effective and risks thyrotoxicosis, especially if autonomy is present.
• Avoid iodine-containing contrast agents - risk of Jod-Basedow effect (enhanced hormone production by autonomous nodules).
• Radioiodine (¹³¹I): Used where surgery is contraindicated; can decrease goiter volume and ablate areas of autonomy. Commonly used in Europe/Brazil for large nodular goiters.
• Surgery: Indicated for compressive symptoms (tracheal/esophageal compression), substernal extension, cosmetic concerns, or suspected malignancy. - Harrison's Principles, p. 3084

---

4. Toxic MNG (Plummer's Disease)

• Antithyroid drugs (ATDs): Normalize function and are particularly useful in the elderly or those with limited life span - though not curative.
• Radioiodine (¹³¹I): Definitive treatment of choice in many patients; selectively ablates autonomous nodules.
• Surgery: Near-total or total thyroidectomy - used when malignancy is suspected (cold nodules with indeterminate/suspicious FNA cytology direct therapy to surgery). - Harrison's Principles, p. 3086

---

5. Graves' Disease (Diffuse Toxic Goiter)

• Beta-blockers (propranolol, atenolol, metoprolol): Control symptoms (palpitations, tremor, tachycardia). Do not affect hormone levels.
• Iodide (Lugol's solution / SSKI): Pre-operative use - reduces gland vascularity. Short-term only (Wolff-Chaikoff effect lasts only days). - Lippincott Pharmacology, p. 785

---

6. Solitary Thyroid Nodule

• Cystic nodules: Ultrasound-guided aspiration ± percutaneous ethanol injection (PEI) for recurrent cysts.
• ACR TI-RADS ultrasound scoring guides which nodules need FNA based on size and sonographic pattern.

---

7. Thyroid Cancer (if malignant cause)

• Papillary/Follicular (differentiated): Total thyroidectomy + RAI ablation + TSH-suppressive LT4 therapy.
• Medullary: Total thyroidectomy + central neck dissection; vandetanib/cabozantinib for advanced disease.
• Anaplastic: Multimodal (surgery where feasible + chemoradiation); extremely poor prognosis.
• Per 2023 ETA guidelines and the 2024 Japan AES guidelines, molecular testing increasingly guides management of indeterminate nodules.

---

8. Hashimoto's Thyroiditis

• If hypothyroid: Levothyroxine (LT4) replacement - goal to normalize TSH.
• If euthyroid: Observation; LT4 may be given to reduce goiter size.
• Surgery: Rarely needed; reserved for compressive symptoms or suspicion of lymphoma.

---

9. Pre-operative Preparation for Thyroid Surgery

• ATDs (methimazole 4-6 weeks) + beta-blockers
• Lugol's iodine for 10 days pre-op (reduces gland vascularity and bleeding risk)
• Scott-Brown's Otorhinolaryngology, p. 1040

---

Quick Reference Summary

Thyroid Swelling
├── Euthyroid diffuse goiter → Iodine replacement / observe / surgery if compressive
├── Nontoxic MNG → Observe; RAI or surgery if symptomatic
├── Toxic MNG → ATDs (short-term) → RAI or surgery
├── Graves' disease → ATDs / RAI / thyroidectomy
├── Solitary nodule → FNA → Bethesda-guided management
├── Thyroid cancer → Surgery ± RAI ± targeted therapy
└── Hypothyroid (Hashimoto's) → Levothyroxine

---

Note: All treatment decisions should factor in patient age, comorbidities, goiter size, functional status, and nodule cytology. Referral to an endocrinologist and/or thyroid surgeon is recommended for definitive management.

---

Thyroid Disease - Comprehensive Treatment & Management (Exam-Level)

---

Overview of Thyroid Conditions

---

1. Hypothyroidism

Causes

• Hashimoto's thyroiditis (most common in iodine-sufficient areas)
• Post-radioiodine or post-thyroidectomy
• Iodine deficiency (most common globally)
• Secondary/tertiary (pituitary or hypothalamic failure)
• Drug-induced (lithium, amiodarone, tyrosine kinase inhibitors)

Treatment: Levothyroxine (LT4) Replacement

• Mechanism: Acts via nuclear receptors; peripheral conversion of T4 → T3 (via Dio1, Dio2) provides T3. - Goodman & Gilman's, p. 2451
• Standard adult dose: 1.7 mcg/kg/day (based on lean body weight)
• Elderly / cardiac disease: Start low at 12.5-50 mcg/day, increase by 25 mcg every 6 weeks
• Monitoring: Check TSH 6-8 weeks after any dose change (reflects the ~7-day T4 half-life)
• Goal: Normalize serum TSH in primary hypothyroidism; normalize free T4 in secondary/tertiary hypothyroidism

• Pregnancy: LT4 dose requirement increases (increased TBG from estrogen + placental Dio3 expression + small transplacental T4 passage); inadequately treated maternal hypothyroidism causes miscarriage, fetal distress, preterm delivery, and impaired neurodevelopment. Per ATA 2026 pregnancy guidelines, proactive dose adjustment is recommended.
• Hashimoto's + goiter: LT4 150-200 mcg/day suppresses TSH, causing slow goiter regression. - Katzung, p. 1304
• Goitrogenic diet: Eliminate goitrogen or add enough T4 to suppress TSH stimulation.
• Goiter from iodine deficiency: Prophylactic/therapeutic iodide supplementation (optimal: 150-200 mcg/day).

• Vast majority of patients do well on LT4 monotherapy alone.
• Combination T4/T3 therapy is not recommended as standard - evidence does not show consistent benefit over T4 alone; however, a small subgroup (particularly those with Dio2 Thr92Ala polymorphism) may feel better on combination therapy. - Goodman & Gilman's, p. 2453

---

2. Hyperthyroidism / Thyrotoxicosis

2A. Graves' Disease

Option 1: Antithyroid Drugs (ATDs) - Thionamides

• Titration regimen (preferred): Gradually reduce dose as euthyroidism is restored; provides index of treatment response.
• Block-replace regimen: Fixed high ATD dose + LT4 added to prevent hypothyroidism.

• Minor: Rash, urticaria, arthralgia, GI disturbance (switch to alternative drug)
• Major (rare): Agranulocytosis (0.2-0.5%) - stop drug immediately; PTU also carries black box warning for hepatotoxicity (potentially fatal)
• Methimazole: Teratogenicity (scalp defects, choanal atresia) - avoid in 1st trimester
• PTU: Preferred in 1st trimester (crosses placenta less, fewer fetal malformations)

Option 2: Radioiodine (¹³¹I / RAI)

• Most commonly used first-line in North America.
• Administered as oral dose of radioactive iodine - concentrated in thyroid, causing radiation-induced thyroid cell destruction over weeks to months.
• Outcome: Intentional hypothyroidism in most patients (followed by lifelong LT4 replacement).
• Contraindications: Pregnancy, breastfeeding (absolute); moderate-severe active Graves' ophthalmopathy (relative - may worsen).
• Pre-treatment: ATDs to achieve euthyroid state before RAI in elderly or those with cardiac disease (to prevent thyroid storm from RAI-induced hormone release).
• Post-RAI: Monitor for hypothyroidism and start LT4.

Option 3: Surgery (Thyroidectomy)

• Near-total or total thyroidectomy - preferred to avoid recurrence and the higher complication rates of reoperation. - Schwartz's Surgery
• Indications: Large goiter causing compressive symptoms, active Graves' ophthalmopathy, desire for prompt definitive treatment, pregnancy planning soon, suspected malignancy, failed ATDs/RAI.
• Pre-operative preparation: Render euthyroid with ATDs (4-6 weeks) + beta-blockers. Give Lugol's iodine (Wolff-Chaikoff effect) 10 days pre-op to reduce gland vascularity.
• Post-operative: LT4 replacement.
• Complications: Hypoparathyroidism (hypocalcemia), recurrent laryngeal nerve injury (hoarseness), bleeding, hypothyroidism.

Adjunct / Symptomatic Treatment

• Beta-blockers (propranolol 40-120 mg/day, atenolol, metoprolol): Rapid control of tachycardia, palpitations, tremor, heat intolerance. Do NOT reduce thyroid hormone levels.
• Iodide (Lugol's / SSKI): Pre-operative use only; blocks hormone release (Wolff-Chaikoff effect) and reduces gland vascularity. Not for long-term use (effect lasts only days). - Lippincott Pharmacology, p. 652

2B. Toxic Multinodular Goiter (Plummer's Disease)

• ATDs: Normalize function, especially for elderly/limited life expectancy (not curative).
• RAI (¹³¹I): Definitive - reduces goiter volume and ablates autonomous regions.
• Surgery: Indicated if malignancy suspected on FNA, or if compressive symptoms.

2C. Thyroid Storm (Thyrotoxic Crisis)

---

3. Thyroiditis

3A. Subacute (de Quervain's) Thyroiditis

3B. Silent / Postpartum Thyroiditis

• Glucocorticoids NOT indicated (unlike subacute thyroiditis)
• Severe thyrotoxic symptoms: brief course of propranolol 20-40 mg TID/QID
• Hypothyroid phase: LT4 (withdraw after 6-9 months - recovery expected)
• Annual follow-up (permanent hypothyroidism develops in some)

3C. Hashimoto's (Chronic Autoimmune) Thyroiditis

• Hypothyroid: LT4 replacement (target: normal TSH)
• Euthyroid + goiter: LT4 to suppress TSH and reduce goiter size
• Euthyroid, no goiter: Observation
• Surgery: Reserved for compressive symptoms or suspicion of thyroid lymphoma

3D. Drug-Induced Thyroiditis

• Treatment same as silent thyroiditis
• Monitor thyroid function routinely during these therapies (ASCO recommendation)

---

4. Thyroid Nodule / Multinodular Goiter

• HIFU (High-Intensity Focused Ultrasound): 2023 meta-analysis (PMID 37478539) supports HIFU for benign thyroid nodules.
• Radiofrequency ablation (RFA): Per 2023 ETA guidelines, thermal ablation techniques (RFA, laser, HIFU) are recommended alternatives to surgery for benign nodules causing symptoms.

---

5. Thyroid Cancer

Types & Prognosis

Treatment of Differentiated Thyroid Cancer (Papillary/Follicular)

• Total thyroidectomy is standard for most differentiated thyroid cancer.
• Hemithyroidectomy may be sufficient for low-risk papillary cancers (<1 cm, no extrathyroidal extension, no nodal disease).
• Central neck dissection if nodal disease present.
• Ref: 2025 ATA Differentiated Thyroid Cancer Guidelines

• Destroys residual thyroid tissue (remnant ablation) and any metastatic disease.
• Used selectively - not all patients need RAI; risk stratification determines use.
• Prior to RAI: TSH must be elevated to drive ¹³¹I uptake. Two options:
  • Withdraw LT4 for 4-6 weeks (patient becomes hypothyroid)
  • Recombinant human TSH (rhTSH / Thyrogen) IM x 2 days - avoids hypothyroidism - Katzung, p. 1314

• LT4 post-surgery kept at dose sufficient to suppress TSH (reduces TSH-driven tumor recurrence).
• Degree of suppression based on risk: high-risk patients → fully suppressed TSH; low-risk → TSH low-normal.

• Serum thyroglobulin (Tg) is the tumor marker - rise indicates recurrence.
• Positive ¹³¹I scan on TSH stimulation confirms recurrence.

• Sorafenib, lenvatinib (tyrosine kinase inhibitors) for RAI-refractory disease.

Medullary Thyroid Cancer (MTC)

• Total thyroidectomy + central neck dissection.
• Tumor marker: Calcitonin and CEA for surveillance.
• Advanced/metastatic: Vandetanib or Cabozantinib (RET kinase inhibitors).
• Screen for RET mutation (familial MTC / MEN2).

Anaplastic Thyroid Cancer

• Surgery if resectable; most are unresectable at diagnosis.
• Multimodal: chemoradiation (doxorubicin + cisplatin).
• Dabrafenib + trametinib for BRAF V600E-mutated anaplastic thyroid cancer (targeted therapy).
• Median survival < 6 months; extremely poor prognosis.

---

6. Drug Summary Table

---

Exam High-Yield Pearls

1. Methimazole is preferred over PTU except in 1st trimester pregnancy and thyroid storm.
2. PTU carries FDA black box warning for liver failure - use only when specifically indicated.
3. Agranulocytosis with ATDs: tell patients to stop the drug and seek urgent medical attention if they develop fever or sore throat.
4. Radioiodine uptake differentiates causes of thyrotoxicosis: HIGH uptake = Graves'/toxic MNG (synthesis-driven); LOW uptake = thyroiditis, exogenous thyroid hormone.
5. TSH is the first and most sensitive screening test for thyroid dysfunction.
6. TSH remains suppressed for months after starting ATDs - use free T4 to monitor treatment response in the first few months.
7. In subacute thyroiditis, ATDs have NO role in the thyrotoxic phase (not a synthesis problem).
8. Amiodarone contains 37% iodine by weight and can cause both hypo- and hyperthyroidism.
9. In thyroid cancer follow-up: rising thyroglobulin on LT4 therapy or positive RAI scan = recurrence.
10. Pregnancy: LT4 dose requirements increase; untreated maternal hypothyroidism impairs fetal neurodevelopment.

---

---

Thyroid Colloid Cyst - Comprehensive Notes

---

Definition

---

Pathology

Normal Thyroid Follicle (Context)

• The thyroid follicle is the basic structural and functional unit of the thyroid gland.
• Each follicle = a roughly spherical, cyst-like compartment lined by follicular epithelium (thyrocytes), with a central colloid lumen rich in thyroglobulin.
• Surrounding stroma contains parafollicular (C) cells, capillaries, connective tissue, and lymphatics.

Colloid Cyst Formation

• Colloid cysts arise from distension and accumulation of colloid within one or more thyroid follicles - often as part of a multinodular goiter process.
• Many result from intranodular ischemia causing tissue necrosis and liquefaction (degenerating adenoma or hyperplastic nodule).
• True epithelial-lined cysts are rare; most "thyroid cysts" are colloid-rich degenerated nodules or partial cysts.
• Approximately 15-25% of all thyroid nodules are cystic or have a cystic component. - Cummings Otolaryngology, p. 3848

Classification of Thyroid Cysts (Pathological)

---

Clinical Features

• Age/Sex: More common in women; increases with age.
• Presentation: Usually a painless, soft, smooth-surfaced swelling in the neck, moves with swallowing.
• Functional status: Typically euthyroid - does not produce excess thyroid hormone.
• Symptoms: Usually asymptomatic; large cysts may cause:
  • Dysphagia (esophageal compression)
  • Dyspnoea / stridor (tracheal compression)
  • Cosmetic concern
  • Sudden pain if hemorrhage occurs into the cyst
• May be discovered incidentally on imaging (ultrasound, CT, MRI).

---

Investigations

1. Thyroid Function Tests

• TSH (first-line) - typically normal in a euthyroid colloid cyst.
• Free T4, T3 if TSH abnormal.

2. Ultrasound (US) - Most Important Imaging

• Anechoic or hypoechoic well-defined lesion
• "Comet tail" artifact - pathognomonic of colloid: bright echogenic focus with posterior reverberation artifact from colloid crystals
• Smooth walls, thin capsule
• Purely cystic or predominantly cystic with minimal solid component

• TR1 (benign) - spongiform nodule with >50% microcystic areas = very low malignancy risk, no FNA needed unless >2 cm
• TR2 - pure cyst = no FNA

3. Fine-Needle Aspiration Cytology (FNAC / FNA)

• The single most important diagnostic test for thyroid masses. - Schwartz's Principles of Surgery, p. 1671
• Uses a 23-gauge needle; multiple passes with aspiration; slides stained with Papanicolaou or Wright's stain.
• US guidance is recommended for cystic, recurrent, or difficult-to-palpate nodules.

4. Thyroid Scintigraphy (Isotope Scan)

• Colloid cysts typically appear as "cold" nodules (non-functioning, reduced isotope uptake).
• Limited diagnostic value; largely replaced by FNA.
• Still useful if TSH is suppressed (to identify "hot"/autonomous nodules).

5. CT / MRI

• For substernal extension, airway compression assessment, or if malignancy suspected.

---

Important: Is Every Cystic Thyroid Nodule Benign?

• Papillary carcinomas may manifest as cystic masses and are present in 14-32% of all cystic thyroid nodules. - Cummings Otolaryngology
• A cystic appearance alone does NOT confirm benignity.
• Suspicion for carcinoma increases if:
  • Cyst reaccumulates after 3 drainage attempts
  • Rapid reaccumulation after drainage
  • Solid component on US (especially hypoechoic, irregular margins, microcalcifications)
  • Red/bloody aspirate
  • History of radiation or family history of thyroid cancer

---

Management

Management Algorithm (from Schwartz's Surgery):

1. Asymptomatic, Confirmed Benign Colloid Cyst

• Observation with periodic ultrasound surveillance (6-12 monthly, then less frequently if stable).
• No treatment required if truly benign and asymptomatic.
• Levothyroxine (T4) suppression is NOT recommended for benign nodules in iodine-sufficient areas (no evidence of benefit; risk of thyrotoxicosis).

2. Symptomatic / Enlarging Cyst - Aspiration (FNAC Drainage)

• Drain the cyst completely at time of FNA - this may be curative for simple cysts.
• One or two additional drainage procedures may be required (cysts commonly reaccumulate).
• If the cyst reaccumulates after 3 drainage attempts → increased suspicion for malignancy → surgery.

3. Percutaneous Ethanol Injection (PEI) - Sclerotherapy

• For recurrent cystic nodules after repeated aspiration failure.
• Ethanol is injected into the cyst cavity under ultrasound guidance, causing sclerosis of the cyst wall.
• A 2024 systematic review and meta-analysis (PMID 39030844) confirmed PEI is effective for cystic thyroid nodules with a low overall complication rate (~2.5%), most commonly transient pain or mild burning sensation.
• Note: Some textbooks (e.g. Cummings) advise caution with sclerosing agents due to potential thyroid carcinoma being missed, and prefer surgery over injection in suspicious cases.

4. Surgery

• Persistent cyst after 3 aspiration attempts
• Rapid reaccumulation
• Suspicious FNA cytology (Bethesda III-VI)
• Solid component with suspicious US features
• Compressive symptoms (dysphagia, stridor) not relieved by aspiration
• Cosmetically unacceptable
• Clinical suspicion of carcinoma (bloody aspirate, hard fixed lesion, lymphadenopathy, hoarseness)

• Unilateral thyroid lobectomy (hemithyroidectomy): For a unilateral cyst - provides definitive diagnosis
• Near-total / total thyroidectomy: If bilateral disease, or confirmed malignancy on frozen section

5. Newer Ablation Techniques (for symptomatic benign cysts)

• Radiofrequency ablation (RFA): Effective for reducing benign cystic/solid thyroid nodules; endorsed by 2023 ETA guidelines.
• HIFU (High-intensity focused ultrasound): Supported by a 2023 meta-analysis (PMID 37478539) for benign thyroid nodules.
• These are alternatives to surgery for patients who decline or are unfit for surgery.

---

Differential Diagnosis of a Cystic Thyroid Mass

---

Prognosis

• True colloid cysts are entirely benign with excellent prognosis.
• Most resolve or remain stable with aspiration.
• Recurrence after single aspiration is common (~50-75%).
• Malignant transformation does not occur in a true colloid cyst.
• The key clinical task is reliably excluding malignancy - which requires FNA cytology (and sometimes surgery).

---

Exam High-Yield Pearls

1. Colloid cyst is a Bethesda II lesion on FNA - management is aspirate and observe.
2. "Comet-tail" artifact on ultrasound = strongly suggests colloid - low malignancy risk.
3. A cyst that reaccumulates ≥3 times after aspiration → suspect malignancy → surgery.
4. Red/bloody aspirate from a thyroid cyst = more suspicious for carcinoma.
5. 14-32% of cystic thyroid nodules may harbor papillary carcinoma - never assume all cysts are benign.
6. Levothyroxine suppression is NOT recommended for benign thyroid nodules.
7. Parathyroid cyst: clear fluid + high PTH in fluid - do not inject it thinking it is a thyroid cyst.
8. PEI (percutaneous ethanol injection) is an effective non-surgical option for recurrent benign cysts.

---

---

Is a Thyroid Colloid Cyst Dangerous?

---

The Reassuring Facts

• About 95% of all thyroid nodules (including colloid cysts) are non-cancerous.
• A colloid cyst confirmed on FNA is classified as Bethesda Category II (Benign) - this is essentially a "do not worry" result.
• Malignant transformation of a true colloid cyst does not occur.

---

When It Could Be a Problem

1. Misidentification - It May Not Be a Pure Colloid Cyst

• 14-32% of cystic thyroid nodules can harbor papillary carcinoma inside them - particularly those with a solid component. - Cummings Otolaryngology
• A cystic appearance on ultrasound alone cannot rule out malignancy.
• This is why FNA (fine-needle aspiration) is essential before concluding a cyst is benign.

2. Warning Signs That Raise Concern

3. Compressive Effects (Large Cysts)

• A large colloid cyst or multinodular goiter may, over time, press on nearby structures causing:
  • Difficulty swallowing (dysphagia)
  • Breathing difficulty or stridor (tracheal compression)
  • Voice changes (laryngeal nerve pressure)
• These mechanical effects can be problematic even in a fully benign cyst.

4. Hemorrhage Into the Cyst

• Sudden pain in a previously painless thyroid lump often signals hemorrhage into a colloid nodule.
• This is not dangerous long-term but causes acute discomfort and rapid enlargement.
• Resolves spontaneously or with aspiration.

---

Bottom Line - Practical Guidance

Thyroid colloid cyst confirmed by FNA (Bethesda II)
→ BENIGN - not dangerous
→ Periodic ultrasound surveillance (6-12 months, then yearly)
→ No surgery needed unless it causes compressive symptoms
   or reaccumulates after 3 aspirations

Thyroid cyst NOT yet evaluated by FNA
→ Needs proper workup (ultrasound + FNA)
→ Do NOT assume it is safe until confirmed

Key message: A confirmed thyroid colloid cyst is benign and carries an excellent prognosis. The real clinical task is making sure it IS genuinely benign - which requires ultrasound assessment and FNA cytology. Once confirmed, it can be safely monitored without surgery in most cases.